J Cancer 2021; 12(9):2654-2664. doi:10.7150/jca.54595 This issue Cite

Research Paper

Overexpression of Galectin10 Predicts a Better Prognosis in Human Ovarian Cancer

Wenxiao Jiang, Mandika Chetry, Shuya Pan, Longyi Wang, Xueqiong Zhu

Department of obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China.

Citation:
Jiang W, Chetry M, Pan S, Wang L, Zhu X. Overexpression of Galectin10 Predicts a Better Prognosis in Human Ovarian Cancer. J Cancer 2021; 12(9):2654-2664. doi:10.7150/jca.54595. https://www.jcancer.org/v12p2654.htm
Other styles

File import instruction

Abstract

Graphic abstract

To explore the prognosis of Galectins (LGALS) expression on patients with ovarian cancer, the prognosis of LGALS members in ovarian cancer was retrieved and analyzed by using 'Kaplan-Meier plotter' database. The relation of LGALS to overall survival (OS) was evaluated according to histological subtypes, clinical stages and pathological grade. Quantitative real-time polymerase chain reaction and western blot were used to detect the mRNA and protein expression of LGALS in ovarian cancer and normal ovarian cells. Immunohistochemistry was applied to evaluate the different expression of LGALS between cancer and normal tissues. In total patients with ovarian cancer, LGALS4, LGALS8, LGALS10 and LGALS13 mRNA levels were related to a better OS, and LGALS1 to a worse OS. LGALS1 predicted a worse OS in women with serous, stages III+IV or grade II ovarian cancer. LGALS4 predicted a better OS in patients with endometrioid, stages I+II or grade III ovarian cancer. LGALS10 predicted a longer OS in females with serous, all stages, or grade III cancer. LGALS8 overexpression was related to a better OS in all stages. Notably, mRNA and protein expressions of LGALS4, LGALS10 and LGALS13 were decreased in cancer cells than those in normal cells (P<0.05). Additionally, the immunostaining score of LGALS8, LGALS10 and LGALS13 expression were lower but LGALS1 was higher in caner tissues than those in normal tissues (P<0.001). In conclusion, LGALS10 possibly is a valuable biomarker for predicting a favorable prognosis in patients with ovarian cancer, especially with serous, all stages and grade III cancer.

Keywords: Galectins (LGALS), Kaplan-Meier Plotter, Ovarian cancer, Prognosis.


Citation styles

APA
Jiang, W., Chetry, M., Pan, S., Wang, L., Zhu, X. (2021). Overexpression of Galectin10 Predicts a Better Prognosis in Human Ovarian Cancer. Journal of Cancer, 12(9), 2654-2664. https://doi.org/10.7150/jca.54595.

ACS
Jiang, W.; Chetry, M.; Pan, S.; Wang, L.; Zhu, X. Overexpression of Galectin10 Predicts a Better Prognosis in Human Ovarian Cancer. J. Cancer 2021, 12 (9), 2654-2664. DOI: 10.7150/jca.54595.

NLM
Jiang W, Chetry M, Pan S, Wang L, Zhu X. Overexpression of Galectin10 Predicts a Better Prognosis in Human Ovarian Cancer. J Cancer 2021; 12(9):2654-2664. doi:10.7150/jca.54595. https://www.jcancer.org/v12p2654.htm

CSE
Jiang W, Chetry M, Pan S, Wang L, Zhu X. 2021. Overexpression of Galectin10 Predicts a Better Prognosis in Human Ovarian Cancer. J Cancer. 12(9):2654-2664.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image